FDA Grants Fast Track Designation for Paradigm Biopharmaceut

Approval demonstrates the potential of Zilosul™ to address an unmet medical need in OA which effects more than 72 million people in the US, EU5, and Canada KEY...

Related Keywords

Canada , Australia , Donna Skerrett , Institute For Health , University Of Washington , Drug Administration , Fast Track Program , Global Health Data Exchange , Paradigm Chief Medical Officer , Fast Track Designation , Track Program , Paradigm Biopharmaceuticals , Pentosan Polysulfate Sodium , Metrics Evaluation , Accessed June , Serious Disease , Drug Administration December ,